{"links":{"feed":"https://www.erudio.com/reports/sgnb6a-001-nct04389632/feed.json","html":"https://www.erudio.com/reports/sgnb6a-001-nct04389632","json":"https://www.erudio.com/reports/sgnb6a-001-nct04389632.json","markdown":"https://www.erudio.com/reports/sgnb6a-001-nct04389632.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"sgnb6a-001-nct04389632"}},"request":"https://www.erudio.com/contact?report=sgnb6a-001-nct04389632"},"offer":{"cited_clinicians":0,"cited_commentary_sources":1,"verified_hcp_statements":3,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":0},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=sgnb6a-001-nct04389632","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=sgnb6a-001-nct04389632","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/sgnb6a-001-nct04389632","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 3 verified statements · none from confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T17:23:26.125275Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":5,"no_commentary_found":5},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Number of participants with adverse events (AEs)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Number of patients with laboratory abnormalities"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Number of participants with dose-limiting toxicities (DLTs)"},{"claim_count":1,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":0,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":1,"coverage":"discussed","id":"A1","source_count":1,"title":"Abstract–ASCO24 presentation consistency"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":1,"title":"Evidence threshold for phase III development"}],"counts":{"cited_clinicians":0,"cited_clinicians_by_role":{},"cited_physicians":0,"cited_sources":1,"claims_by_expression_type":{"opinion":1,"question":1,"uncertainty":1},"claims_by_kind":{"source_observation":3},"clinician_statements":0,"evidence_units":4,"findings":2,"people_cited":1,"people_identity_verified":0,"people_total":2,"screened_sources":17,"verified_claims":3},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"SGNB6A-001: a speaker questions subgrouping, reporting and PFS precision","title_holders":{"cited_claim_ids":["claim-5552621b75d51e6f393e","claim-57681d6b63c837f7d2f9"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":0,"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":0},"limitations":1,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"SGNB6A-001: why a speaker questions a phase III launch on subgroup data","title_holders":{"cited_claim_ids":["claim-ab7e368dca33badfd5e2"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account challenges how the subgroup evidence was selected and presented"},{"id":"section-2","level":2,"title":"One X account asks whether the evidence justified launching phase III"},{"id":"section-3","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, sequential, phase1","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Number of participants with adverse events (AEs)"},{"findings":[],"id":"T2","label":"Primary endpoint: Number of patients with laboratory abnormalities"},{"findings":[],"id":"T3","label":"Primary endpoint: Number of participants with dose-limiting toxicities (DLTs)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[],"id":"T6","label":"The comparison"},{"findings":[],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T17:23:26.125275Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T17:32:23Z","record_hash":"b4ea9fba753063ca3cfbd94700ff45fff0bc7705f48f94008c670982c9adf421","release_hash":"106161623e8afe602645b571e72a302adf0a9f24a336f7c186362b719275bd46","report_id":"erudio-nct04389632","run_id":"48269a99-83b8-44c8-96ef-b8eb6e6141c2","schema_version":"5.0","slug":"sgnb6a-001-nct04389632","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A speaker questions the credibility of SGNB6A-001’s subgroup evidence, citing repeated patient subdivisions, but the criticism does not establish improper analysis. For the nonsquamous, taxane-naive subgroup, prespecification and the alleged discrepancy between abstract and presentation remain unresolved. The speaker’s clinical role could not be confirmed. The sources place these phase I results in NSCLC at ASCO 2024.","examples":[],"meta_description":"17 sources screened · 3 verified statements (0 from clinicians verified by NPI or staff page) from 1 source · 2 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T17:32:23Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":17},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on efficacy and tolerability in lung cancer, including taxane-naive nonsquamous disease.","19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 31 sources about other trials or topics are not included.","The cited substantive views come from one X account on 1 June 2024 and do not show how widely HCPs share them.","Coverage of public discussion is incomplete: comments without recognizable trial identifiers or trial/drug names, including some transcription variants, may be missing.","The reviewed posts do not establish whether the subgroup analyses were prespecified, independently reconcile the abstract with the presentation, or provide numerical confidence-interval limits."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":1,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":1},"count":1,"evidence_window":{"end":"2024-06-01","start":"2024-06-01"},"retrieval_snapshot":"2026-11-21T17:07:23.918488Z","timeline":[{"count":1,"week":"2024-W22"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04389632:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04389632:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:37619980","quote_policy":"no_derivatives"},{"id":"openfda:9333c79b-d487-4538-a9f0-71b91a02b287:20261016","quote_policy":"short_quote_link_out"},{"id":"openfda:93edf309-993c-48ec-be90-27d89c86b62b:20261112","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-5xpa74q7sm6ajcvoc5lxltez-3lqmuamixq22q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-a2oecitqmf5cyghbram6kwxe-3lqfwi3y3f22e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715383543604400583:32d33f16-ad40-46b8-b65c-023967290e66","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715396404154429824:248bb297-9a19-43aa-94c9-4a0a4a28b70a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783147239101337772:5e3a6332-245d-4879-a584-c089172df02e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789688397814026735:9059e83a-27e6-43a2-9ff7-f18e3256a930","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1795822127658246487:e1f42733-8f75-4586-943d-e7ad9072e4fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797020799305425146:3d12bb49-c0f5-4f13-afcc-347ee2dfdc57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797037107988378098:75a1d2c2-9e77-4999-a1ce-14679c8aca9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797038070581067934:c0016474-1eb3-4fce-a376-ad05e6f8c210","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797045134569132420:797ec9d5-fb33-4114-b711-addeae13ff20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835240768912429109:1bca525b-60a8-4141-8dc4-51d17c59ac6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1935976379805560877:a82726c6-7580-4fbd-8d2f-1a4d2cff9fb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1935976892500226468:9a9fdd72-42e1-4147-aba0-fb2a3b5c224e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1962259098063261970:8e713cb9-8c75-464e-a5ee-26ea9d4e1000","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046350146640720269:7bbb983d-1d10-49f2-81bc-998af093b328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121240422668210311:662b1618-14e1-4f51-b048-25db1d242d93","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":17},"count":17,"evidence_window":{"end":"2026-11-13","start":"2023-10-20"},"retrieval_snapshot":"2026-11-21T17:07:24.438309Z","timeline":[{"count":2,"week":"2023-W42"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W19"},{"count":5,"week":"2024-W22"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W23"},{"count":2,"week":"2025-W25"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"sigvotatug vedotin","slug":"sigvotatug-vedotin"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Head and neck squamous cell carcinoma","slug":"head-and-neck-squamous-cell-carcinoma"},{"reason":"Unmapped registry condition: HER2 Negative Breast Neoplasms","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Esophageal squamous cell carcinoma","slug":"esophageal-squamous-cell-carcinoma"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Esophageal adenocarcinoma","slug":"esophageal-adenocarcinoma"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Gastroesophageal adenocarcinoma","slug":"gastroesophageal-adenocarcinoma"},{"reason":"Unmapped registry condition: Ovarian Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Cutaneous Squamous Cell Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Exocrine Pancreatic Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Urinary Bladder Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Uterine Cervical Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Stomach Neoplasms","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SGNB6A-001","aliases":["SGNB6A-001","A Study of Sigvotatug Vedotin in Advanced Solid Tumors","A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors"],"brief_title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Carcinoma, Non-Small Cell Lung","Squamous Cell Carcinoma of Head and Neck","HER2 Negative Breast Neoplasms","Esophageal Squamous Cell Carcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Ovarian Neoplasms","Cutaneous Squamous Cell Cancer","Exocrine Pancreatic Adenocarcinoma","Urinary Bladder Neoplasms","Uterine Cervical Neoplasms","Stomach Neoplasms"],"display_condition":"advanced solid tumors","display_interventions":[["sigvotatug vedotin (SGN-B6A)"],["sigvotatug vedotin (SGN-B6A)","pembrolizumab","platinum-based chemotherapy"]],"enrollment":{"count":1006,"type":"ESTIMATED"},"interventions":[{"name":"sigvotatug vedotin","synonyms":["SGN-B6A","PF-08046047"],"type":"DRUG"},{"name":"pembrolizumab","synonyms":["Keytruda"],"type":"DRUG"},{"name":"cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04389632","official_title":"A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors","overall_status":"RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-06-16","type":"ESTIMATED"},"primary_endpoints":[{"description":"Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.","measure":"Number of participants with adverse events (AEs)","timeFrame":"Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years"},{"measure":"Number of patients with laboratory abnormalities","timeFrame":"Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years"},{"measure":"Number of participants with dose-limiting toxicities (DLTs)","timeFrame":"Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years"}],"registered_date":{"date":"2020-05-15","type":"ACTUAL"},"registry_last_updated":"2026-07-06","registry_url":"https://clinicaltrials.gov/study/NCT04389632","short_name":"SGNB6A-001","short_name_basis":"canonical_name","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","start_date":{"date":"2020-06-08","type":"ACTUAL"},"study_design":"interventional, na, sequential, phase1","study_ids":[{"id":"SGNB6A-001","type":"sponsor_study_id"},{"domain":"Alias Study Number","id":"C5751001","type":"other"},{"domain":"CTIS (EU)","id":"2023-508469-34-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}